Advertisement

Bronchospasmolytika und Antiasthmatika

  • Björn Lemmer

Zusammenfassung

Betasympathomimetika bilden traditionell die größte Arzneimittelgruppe in der Asthmatherapie. Die Domäne der kurzwirkenden Substanzen ist die inhalative Akutbehandlung des Asthmaanfalls. Langwirkende Betasympathomimetika werden jetzt überwiegend in Kombinationspräparaten mit inhalativen Glucocorticoiden verordnet

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agertoft L, Pedersen S (2000): Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 343: 1064–1069.PubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (2003): Arzneiverordnungen. 20. Aufl., Deutscher Ärzte-Verlag, Köln, S. 610.Google Scholar
  3. Barnes PJ (1995): Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152: 838–860.PubMedGoogle Scholar
  4. Barnes PJ, Pauwels RA (1994): Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J. 7: 579–591.PubMedCrossRefGoogle Scholar
  5. Bundesamt für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachung gemäß § 26, Abs. 3 AMG vom 19.1.1998.Google Scholar
  6. Brocklebank D, Wright J, Cates Ch (2001): Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Brit. Med. J. 323:1–7.CrossRefGoogle Scholar
  7. Buhl R, Kardos P, Magnussen H, Matthys H, Sauer R, Schauer P et al. (1999): Feste Kombination inhalierbarer Kortikoide und langwirkender β2-Sympathomime-tika zur Langzeittherapie des Asthma bronchiale. Pneumologie 53: 210–212.PubMedGoogle Scholar
  8. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J et al. (1999): Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new prolellant. J. Allergy Clin. Immunol. 104:1215–1222.PubMedCrossRefGoogle Scholar
  9. Clarke PS, Ratowsky DA (1990): Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Ann. Allergy 64(2 Pt. 2): 187–190.PubMedGoogle Scholar
  10. Crout JR (1974): Fixed combination prescription drugs: FDA policy. J. Clin. Pharmacol. 14: 249–254.PubMedGoogle Scholar
  11. Debelic M, Hertel G, König J (1988): Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma. Ann. Allergy 61: 25–29.PubMedGoogle Scholar
  12. Drazen JM, Israel E, O’Byrne PM (1999): Treatment of asthma with drugs modifying the leukotrien pathway. N. Engl. J. Med. 340:197–206.PubMedCrossRefGoogle Scholar
  13. Ducharme FM, Hicks GC (2001): Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. The Cochrane Library, Issue 2. Oxford: Update Software.Google Scholar
  14. Ducharme FM (2003): Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Brit. Med. J. 326:619.CrossRefGoogle Scholar
  15. Gehrke I, Bohm E, Sybrecht GW (1986): Stress-induced asthma — placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two. Prax. Klin. Pneumol. 40: 129–134.PubMedGoogle Scholar
  16. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2003): Pocket guide to COPD Managmenent, Diagnosis, and Prevention. http://www.goldcopd.com/revised_gp.pdf, updated July 2003, aufgerufen 9.5.2004.Google Scholar
  17. Grahnén A, Eckernas SA, Brundin RM, Ling-Andersson A (1994): An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38: 521–525.PubMedCrossRefGoogle Scholar
  18. Hanania NA, Chapman KR, Sturtridge WC. et al. (1995): Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 96: 571–579.PubMedCrossRefGoogle Scholar
  19. Jarvis B, Markham A. (2000): Montelukast — a review of its therapeutic potential in persistent asthma. Drugs 59: 891–928.PubMedCrossRefGoogle Scholar
  20. Leach C, Davidson PJ, Boudreau RJ (1998): Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclome-thasone. Eur. Respir. J. 12:1346–1353.PubMedCrossRefGoogle Scholar
  21. Lemmer B (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82.Google Scholar
  22. Lemmer B, Wettengel R (2004): Erkrankungen der Atemwege. In: Lemmer B, Brune K (Hrsg.): Pharmakotherapie — Klinische Pharmakologie. 12. Aufl., Springer Verlag, Berlin Heidelberg New York, S. 347–366.Google Scholar
  23. Lipworth BJ (1999): Modern drug treatment of chronic asthma. Brit. Med. J. 318: 380–383.PubMedCrossRefGoogle Scholar
  24. Markham A, Jarvis B (2000): Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 60:1207–1233.PubMedCrossRefGoogle Scholar
  25. McCowan C, Neville RG, Thomas GE, Crombie IK, Clark RA et al. (1998): Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. Brit. Med. J. 316: 668–672.PubMedCrossRefGoogle Scholar
  26. National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics-2002 [EPR-Update 2002] (2002). NIH Publication No. 02-5074, June 2003. http://www.nhlbi.nih.gov/guidelines/asthma/index.htm.Google Scholar
  27. Parfitt K (1999): Martindale. The complete drug reference. 32nd ed. Pharmaceutical Press, London, pp. 765–774.Google Scholar
  28. Robinson DS, Campbell D, Barnes PJ (2001): Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 357:2007–2011.PubMedCrossRefGoogle Scholar
  29. Rodrigo G, Rodrigo C, Burschtin O (1999): A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 107: 363–370.PubMedCrossRefGoogle Scholar
  30. Schmidt H (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs-Lungenkr. 20: 223–231.Google Scholar
  31. Sears MR, Rea HH, Fenwick J et al. (1987): 75 Deaths in asthmatics prescibed home nebulisers. Brit. Med. J. 294:477–480.CrossRefGoogle Scholar
  32. Smolensky MH, D’Alonso GE (1997): Progress in the chronotherapy of nocturnal asthma. In: Redfern P, Lemmer B (eds.): Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, Vol. 125, Springer, Berlin, Heidelberg, New York, pp. 205–249.Google Scholar
  33. The Childhood Asthma Management Program Research Group [CAMP 2000] (2000): Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 343: 1054–1063.CrossRefGoogle Scholar
  34. Undem BJ, Lichtenstein LM (2001): Drugs used in the treatment of asthma. In: Hardman JH, Limbird LE, Goodman Gilman A (eds): Goodman & Gilman The Pharmacological Basis of Therapeutics, 10th ed. McGraw Hill, New York, pp. 733–754.Google Scholar
  35. van der Wouden JC, Tasche MJ, Bernsen RM et al. (2003): Inhaled sodium cromogly-cate for asthma in children. Cochrane Database Syst. Rev. 2003.Google Scholar
  36. Von Berg A, Albrecht B, Darlath W, Voß HW, Berdel D (2002): Intraindividuelle, ran-domisierte Doppelblindstudie zum Vergleich des protektiven Effektes zwischen verschiedenen Anwendungsformen von DNCG und Reproterol bei Kindern mit Anstrengungsasthma. Allergologie 25: 557–564.Google Scholar
  37. Weinberger M, Hendeles L (1996): Theophylline in asthma. N. Engl. J. Med. 334: 1380–1388.PubMedCrossRefGoogle Scholar
  38. Wettengel R, Berdel D, Hofmann D et al. (1998): Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med. Klinik 93: 639–650.CrossRefGoogle Scholar
  39. Wilson AM, Lipworth BJ, (1999): 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 54: 20–26.PubMedCrossRefGoogle Scholar
  40. Wohl MEB, Majzoub JA (2000): Asthma, steroids, and growth. N. Engl. J. Med. 343: 1113–1114.PubMedCrossRefGoogle Scholar
  41. Worth H et al. (2002): Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 56: 704–738.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Björn Lemmer
    • 1
  1. 1.Institut für Pharmakologie und ToxikologieFakultät für Klinische Medizin Mannheim der Universität HeidelbergMannheim

Personalised recommendations